Form SC 13D/A eFFECTOR Therapeutics, Filed by: US VENTURE PARTNERS X LP
Tweet
Share
E-mail
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13D
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a)
(Amendment No. 2)
eFFECTOR Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
28202V108
(CUSIP Number)
Dale Holladay
c/o U.S. Venture Partners
1460 El Camino Real, Suite 100
Menlo Park, CA 94025
COPY TO:
Christine Wichrowski, Esq.
c/o Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
500 Allerton Street, Redwood City, California 94063
(650) 321-2400
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
August 9, 2022
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ¨.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter disclosures provided in the cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
(Continued on following pages)
| CUSIP No. 28202V108 | 13D | Page 2 of 10 Pages |
1 |
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (Entities Only). U.S. Venture Partners X, L.P. (“USVP X”)
| |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) |
(a) ¨ (b) x |
3 |
SEC USE ONLY | |
4 |
SOURCE OF FUNDS |
OO
|
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
|
¨ |
6 |
CITIZENSHIP
OR PLACE OF ORGANIZATION |
Delaware |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER. 0 shares.
|
| 8 | SHARED VOTING POWER See response to row 7. | |
| 9 | SOLE
DISPOSITIVE POWER 0 shares. | |
| 10 | SHARED DISPOSITIVE POWER See response to row 9. |
11 |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH |
0 |
12 |
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) |
¨ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
0.0% |
14 |
TYPE OF REPORTING PERSON (See Instructions) |
PN |
| CUSIP No. 28202V108 | 13D | Page 3 of 10 Pages |
1 |
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (Entities Only). USVP X Affiliates, L.P. (“AFF X”)
| |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) |
(a) ¨ (b) x |
3 |
SEC USE ONLY | |
4 |
SOURCE OF FUNDS |
OO
|
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
|
¨ |
6 |
CITIZENSHIP
OR PLACE OF ORGANIZATION |
Delaware |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER. 0 shares.
|
| 8 | SHARED VOTING POWER See response to row 7. | |
| 9 | SOLE
DISPOSITIVE POWER 0 shares. | |
| 10 | SHARED DISPOSITIVE POWER See response to row 9. |
11 |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH |
0 |
12 |
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) |
¨ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
0.0% |
14 |
TYPE OF REPORTING PERSON (See Instructions) |
PN |
| CUSIP No. 28202V108 | 13D | Page 4 of 10 Pages |
1 |
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (Entities Only). Presidio Management Group X, L.L.C. (“PMG X”)
| |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) |
(a) ¨ (b) x |
3 |
SEC USE ONLY | |
4 |
SOURCE OF FUNDS |
OO
|
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
|
¨ |
6 |
CITIZENSHIP
OR PLACE OF ORGANIZATION |
Delaware |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER 0 shares.
|
| 8 | SHARED VOTING POWER See response to row 7. | |
| 9 | SOLE
DISPOSITIVE POWER. 0 shares. | |
| 10 | SHARED DISPOSITIVE POWER See response to row 9. |
11 |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH |
0 |
12 |
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) |
¨ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
0.0% |
14 |
TYPE OF REPORTING PERSON (See Instructions) |
OO |
| CUSIP No. 28202V108 | 13D | Page 5 of 10 Pages |
1 |
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (Entities Only). Casey M. Tansey
| |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) |
(a) ¨ (b) x |
3 |
SEC USE ONLY | |
4 |
SOURCE OF FUNDS |
OO
|
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |
¨ |
6 |
CITIZENSHIP
OR PLACE OF ORGANIZATION |
US |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER. 0 shares. |
| 8 |
SHARED VOTING POWER. 0 shares. | |
| 9 |
SOLE DISPOSITIVE POWER. 0 shares. | |
| 10 |
SHARED DISPOSITIVE POWER. 0 shares. |
11 |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH |
0 |
12 |
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) |
¨ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
0.0% |
14
|
TYPE OF REPORTING PERSON (See Instructions) |
IN |
| CUSIP No. 28202V108 | 13D | Page 6 of 10 Pages |
1 |
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (Entities Only). Jonathan D. Root
| |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) |
(a) ¨ (b) x |
3 |
SEC USE ONLY | |
4 |
SOURCE OF FUNDS |
OO
|
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |
¨ |
6 |
CITIZENSHIP
OR PLACE OF ORGANIZATION |
US |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
SOLE VOTING POWER. 0 shares. |
| 8 |
SHARED VOTING POWER. 0 shares. | |
| 9 |
SOLE DISPOSITIVE POWER. 0 shares. | |
| 10 |
SHARED DISPOSITIVE POWER. 0 shares. |
11 |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH |
0 |
12 |
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) |
¨ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
0.0% |
14
|
TYPE OF REPORTING PERSON (See Instructions) |
IN |
| CUSIP No. 28202V108 | 13D | Page 7 of 10 Pages |
| ITEM 1. | SECURITY AND ISSUER. |
This Amendment No. 2 supplements and amends the Schedule 13D that was originally filed on August 25, 2021 (as amended by Amendment No. 1 on May 10, 2022, the “Original Schedule 13D”) relating to the common stock, par value $0.0001 per share (the “Common Stock”), of eFFECTOR Therapeutics, Inc., a Delaware corporation (the “Company”) and is being filed to report the sale of Common Stock of the Company held by certain of the Reporting Persons. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Capitalized terms not defined in this Amendment No. 1 have the meanings ascribed to them in the Original Schedule 13D. The Company’s principal executive offices are located at 11120 Roselle Street, Suite A, San Diego, California. Information given in response to each item shall be deemed incorporated by reference in all other items as applicable.
| ITEM 3. | SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. |
The information set forth in Item 4 hereof is hereby incorporated by reference into this Item 3, as applicable.
Item 3 of Schedule 13D is hereby amended by adding the following to the end thereof:
USVP X sold shares of the Issuer’s Common Stock on the open market as set forth below:
| Date of Transaction | Number of shares of Common Stock |
Price per share |
| 5/11/2022 | 4,845 | 2.345 |
| 5/12/2022 | 10,464 | 2.003 |
| 5/13/2022 | 21,906 | 1.839 |
| 5/16/2022 | 12,374 | 1.746 |
| 5/17/2022 | 11,402 | 1.749 |
| 5/18/2022 | 13,649 | 1.734 |
| 5/19/2022 | 8,308 | 1.690 |
| 7/15/2022 | 44,477 | 1.108 |
| 7/18/2022 | 20,352 | 1.080 |
| 7/19/2022 | 2,670 | 1.000 |
| 7/20/2022 | 9,726 | 1.001 |
| 7/21/2022 | 2,584 | 0.955 |
| 7/22/2022 | 7,383 | 0.910 |
| 7/25/2022 | 2,210 | 0.931 |
| 7/26/2022 | 2,691 | 0.904 |
| 7/27/2022 | 42,344 | 0.892 |
| 7/28/2022 | 31,533 | 0.892 |
| 8/1/2022 | 25,896 | 0.786 |
| 8/2/2022 | 27,348 | 0.797 |
| 8/3/2022 | 57,580 | 0.804 |
| 8/9/2022 | 3,981,940 | 1.003 |
| CUSIP No. 28202V108 | 13D | Page 8 of 10 Pages |
AFF X sold shares of the Issuer’s Common Stock on the open market as set forth below:
| Date of Transaction | Number of shares of Common Stock |
Price per share |
| 5/11/2022 | 155 | 2.346 |
| 5/12/2022 | 336 | 2.003 |
| 5/13/2022 | 701 | 1.839 |
| 5/16/2022 | 395 | 1.746 |
| 5/17/2022 | 365 | 1.750 |
| 5/18/2022 | 437 | 1.734 |
| 5/19/2022 | 266 | 1.689 |
| 7/15/2022 | 1,423 | 1.108 |
| 7/18/2022 | 635 | 1.081 |
| 7/19/2022 | 84 | 1.000 |
| 7/20/2022 | 304 | 1.001 |
| 7/21/2022 | 81 | 0.956 |
| 7/22/2022 | 231 | 0.911 |
| 7/25/2022 | 69 | 0.931 |
| 7/26/2022 | 84 | 0.904 |
| 7/27/2022 | 1,321 | 0.892 |
| 7/28/2022 | 984 | 0.892 |
| 8/1/2022 | 807 | 0.786 |
| 8/2/2022 | 853 | 0.797 |
| 8/3/2022 | 1,796 | 0.804 |
| 8/9/2022 | 127,569 | 1.003 |
| ITEM 4. | PURPOSE OF TRANSACTION. |
The information set forth in Item 3 hereof is hereby incorporated by reference into this Item 4, as applicable.
Item 4 is hereby amended to add the following statements:
| ITEM 5. | INTEREST IN SECURITIES OF THE ISSUER. |
(a,b) Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person. Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person. Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting Person. Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person. Regarding sole power to dispose of shares, see Row 9 of the cover page of each Reporting Person. Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person.
(c) Except as set forth in Item 3 above, the Reporting Persons have not effected any transaction in the common stock of the Issuer during the past 60 days.
On August 9, 2022, certain of the Reporting Persons sold 4,109,509 shares of Common Stock of the Company. On August 9, 2022, the closing price of the Common Stock on the New York Stock Exchange was $0.6520 per share.
| CUSIP No. 28202V108 | 13D | Page 9 of 10 Pages |
(d) Under certain circumstances set forth in the limited partnership agreements of USVP X and AFF X, the limited liability company agreement of PMG X, the partners and the members of each of such entities, as applicable, may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Company owned by each such entity of which they are a partner or member.
(e) The Reporting Persons ceased to be beneficial owners of more than five percent of the Issuer’s Common Stock on August 9, 2022.
| CUSIP No. 28202V108 | 13D | Page 10 of 10 Pages |
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: August 18, 2022
|
PRESIDIO MANAGEMENT GROUP X, L.L.C.
U.S. Venture Partners X, L.P.
USVP X AFFILIATES, L.P.
|
Jonathan D. Root CASEY M. TANSEY
|
| By: | /s/ Dale Holladay | By: | /s/ Dale Holladay | |
| Dale Holladay, Chief Financial Officer/Attorney-In-Fact for the above-listed entities | Dale Holladay, Attorney-In-Fact for the above-listed individuals |
*Signed pursuant to a Power of Attorney already on file with the appropriate agencies.
Create E-mail Alert Related Categories
SEC FilingsRelated Entities
13DSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
